An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A big clinical trial is being launched to see whether semaglutide — the drug in popular weight-loss and diabetes medicines like Ozempic and Wegovy — can help adults who have alcohol use disorder or opioid use disorder. The announcement is about the trial starting; it doesn’t report final results yet. Researchers will enroll people with these substance problems and give some of them semaglutide to compare against a control group. Semaglutide is a man-made version of a naturally occurring gut hormone that affects appetite and blood sugar. In plain terms, it tells your body and brain to feel fuller and also changes how the body handles glucose. That’s why it’s approved for diabetes and for weight loss at certain doses. It is not, so far, approved specifically as a treatment for alcohol or opioid addiction. What the trial aims to test is whether semaglutide can reduce cravings, use, or relapse in people addicted to alcohol or opioids. The news is about the study being organized rather than about proof it works. That means we don’t yet know if it helps, how well it might help, or who would benefit most. The study will enroll a number of participants and follow them over time to collect data; until the trial finishes and the results are analyzed, any effect size is unknown. This matters because addiction to alcohol and opioids causes a lot of harm, and current treatments don’t work for everyone. If semaglutide shows benefit, it could become another tool clinicians use to help people cut down or stop using these substances. People with alcohol or opioid problems, clinicians, and health systems would be most interested because an effective new treatment could reduce overdoses, hospitalizations, and long-term health damage. There are important caveats. Semaglutide has side effects such as nausea, vomiting, and possible digestive issues, and long-term risks are still being studied. It’s approved for diabetes and obesity, not yet for treating substance use disorders, so using it off-label would be experimental. The trial will also need to show safety and effectiveness specifically in people with addiction, who may have other health issues or be taking other medications. Until we have trial results, the drug should not be assumed to be a proven addiction treatment. Bottom line: A major study is now testing whether semaglutide can help people with alcohol or opioid use disorders, but results are pending and it is not yet an approved treatment for those conditions.
Source: News-Medical